p21Cip1 modulates arterial wound repair through the stromal cell-derived factor-1/CXCR4 axis in mice

Journal of Clinical Investigation

Volumn 118, Issue 6, 2008, Pages 2050-2061

  Olive, Michelle ^a   Mellad, Jason A ^b   Beltran, Leilani E ^b   Ma, Mingchao ^b   Cimato, Thomas ^b   Noguchi, Audrey C ^b   San, Hong ^a   Childs, Richard ^b   Kovacic, Jason C ^b   Boehm, Manfred ^b  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CYCLIN DEPENDENT KINASE INHIBITOR 1; JANUS KINASE; STAT PROTEIN; STAT3 PROTEIN; CDKN1A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; PROTEIN P53; STROMAL CELL DERIVED FACTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY INJURY; ARTICLE; BINDING SITE; BONE MARROW TRANSPLANTATION; CELL INFILTRATION; CELL INTERACTION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; FEMORAL ARTERY; IMMUNOCOMPETENT CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SMOOTH MUSCLE FIBER; WOUND HEALING; ANIMAL; APOPTOSIS; BIOLOGICAL MODEL; BIOSYNTHESIS; HOMOZYGOTE; METABOLISM; PATHOLOGY; T LYMPHOCYTE; TIME; TRANSGENIC MOUSE;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CHEMOKINE CXCL12; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMORAL ARTERY; HOMOZYGOTE; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; RECEPTORS, CXCR4; T-LYMPHOCYTES; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; WOUND HEALING;

EID: 45749105047     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI31244     Document Type: Article

References (66)

1. Libby, P. 2002. Inflammation in atherosclerosis. Nature. 420:868-874.
2. Binder, C.J., et al. 2002. Innate and acquired immunity in atherogenesis. Nat. Med. 8:1218-1226.
3. Sata, M., et al. 2002. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat. Med. 8:403-409.
4. Boehm, M., et al. 2004. Bone marrow-derived immune cells regulate vascular disease through a p27(Kip1)-dependent mechanism. J. Clin. Invest. 114:419-426.
5. Grunewald, M., et al. 2006. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell. 124:175-189.
6. Chen, S., et al. 2005. Transforming growth factor-beta1 increases CXCR4 expression, stromal-derived factor-1alpha-stimulated signalling and human immunodeficiency virus-1 entry in human monocyte derived macrophages. Immunology. 114:565-574.
7. Busillo, J.M., and Benovic, J.L. 2007. Regulation of CXCR4 signaling. Biochim. Biophys. Acta. 1768:952-963.
8. Schecter, A.D., Berman, A.B., and Taubman, M.B. 2003. Chemokine receptors in vascular smooth muscle. Microcirculation. 10:265-272.
9. Vila-Coro, A.J., et al. 1999. The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J. 13:1699-1710.
10. Moepps, B., et al. 1997. Two murine homologues of the human chemokine receptor CXCR4 mediating stromal cell-derived factor 1alpha activation of Gi2 are differentially expressed in vivo. Eur. J. Immunol. 27:2102-2112.
11. Sherr, C.J., and Roberts, J.M. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1501-1512.
12. Sherr, C.J., and Roberts, J.M. 2004. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 18:2699-2711.
13. el-Deiry, W.S., et al. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:817-825.
14. Gu, Y., Turck, C.W., and Morgan, D.O. 1993. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature. 366:707-710.
15. Harper, J.W., Adami, G.R., Wei, N., Keyomarsi, K., and Elledge, S.J. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:805-816.
16. Xiong, Y., et al. 1993. p21 is a universal inhibitor of cyclin kinases. Nature. 366:701-704.
17. Suzuki, A., Tsutomi, Y., Akahane, K., Araki, T., and Miura, M. 1998. Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene. 17:931-939.
18. Cheng, M., et al. 1999. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 18:1571-1583.
19. LaBaer, J., et al. 1997. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11:847-862.
20. Seoane, J., Le, H.V., and Massague, J. 2002. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature. 419:729-734.
21. Merched, A.J., and Chan, L. 2004. Absence of p21Waf1/Cip1/Sdi1 modulates macrophage differentiation and inflammatory response and protects against atherosclerosis. Circulation. 110:3830-3841.
22. Scatizzi, J.C., et al. 2006. p21Cip1 is required for the development of monocytes and their response to serum transfer-induced arthritis. Am. J. Pathol. 168:1531-1541.
23. Chang, M.W., Barr, E., Lu, M.M., Barton, K., and Leiden, J.M. 1995. Adenovirus-mediated overexpression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J. Clin. Invest. 96:2260-2268.
24. Condorelli, G., Aycock, J.K., Frati, G., and Napoli, C. 2001. Mutated p21/WAF/CIP transgene overexpression reduces smooth muscle cell proliferation, macrophage deposition, oxidation-sensitive mechanisms, and restenosis in hypercholesterolemic apolipoprotein E knockout mice. FASEB J. 15:2162-2170.
25. Sata, M., et al. 2002. Mouse genetic evidence that tranilast reduces smooth muscle cell hyperplasia via a p21(WAF1)-dependent pathway. Arterioscler. Thromb. Vasc. Biol. 22:1305-1309.
26. Yang, Z.Y., et al. 1996. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc. Natl. Acad. Sci. U. S. A. 93:7905-7910.
27. Tanner, F.C., et al. 2000. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation. 101:2022-2025.
28. Otterbein, L.E., et al. 2003. Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury. Nat. Med. 9:183-190.
29. Diez-Juan, A., et al. 2004. Selective inactivation of p27(Kip1) in hematopoietic progenitor cells increases neointimal macrophage proliferation and accelerates atherosclerosis. Blood. 103:158-161.
30. Moses, J.W., et al. 2003. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349:1315-1323.
31. Suzuki, T., et al. 2001. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 104:1188-1193.
32. Mancini, D., et al. 2003. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation. 108:48-53.
33. Carter, A.J., et al. 2004. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc. Res. 63:617-624.
34. Perkins, N.D. 2002. Not just a CDK inhibitor: regulation of transcription by p21(WAF1/CIP1/SDI1). Cell Cycle. 1:39-41.
35. Coqueret, O. 2003. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol. 13:65-70.
36. Kitaura, H., et al. 2000. Reciprocal regulation via protein-protein interaction between c-Myc and p21(cip1/waf1/sdi1) in DNA replication and transcription. J. Biol. Chem. 275:10477-10483.
37. Coqueret, O., and Gascan, H. 2000. Functional interaction of STAT3 transcription factor with the cell cycle inhibitor p21WAF1/CIP1/SDI1. J. Biol. Chem. 275:18794-18800.
38. Delavaine, L., and La Thangue, N.B. 1999. Control of E2F activity by p21Waf1/Cip1. Oncogene. 18:5381-5392.
39. Harris, T.E., Albrecht, J.H., Nakanishi, M., and Darlington, G.J. 2001. CCAAT/enhancer-binding protein-alpha cooperates with p21 to inhibit cyclin-dependent kinase-2 activity and induces growth arrest independent of DNA binding. J. Biol. Chem. 276:29200-29209.
40. Tanner, F.C., et al. 1998. Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ. Res. 82:396-403.
41. Bruhl, T., et al. 2004. p21Cip1 levels differentially regulate turnover of mature endothelial cells, endothelial progenitor cells, and in vivo neovascularization. Circ. Res. 94:686-692.
42. Maejima, Y., et al. 2003. Nitric oxide inhibits ischemia/reperfusion- induced myocardial apoptosis by modulating cyclin A-associated kinase activity. Cardiovasc. Res. 59:308-320.
43. Zhang, C., Kavurma, M.M., Lai, A., and Khachigian, L.M. 2003. Ets-1 protects vascular smooth muscle cells from undergoing apoptosis by activating p21WAF1/Cip1: ETS-1 regulates basal and and inducible p21WAF1/Cip: ETS-1 regulates basal and inducible p21WAF1/Cip1 transcription via distinct cis-acting elements in the p21WAF/Cip1 promoter. J. Biol. Chem. 278:27903-27909.
44. Beuvink, I., et al. 2005. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell. 120:747-759.
45. Duckers, H.J., et al. 2001. Heme oxygenase-1 protects against vascular constriction and proliferation. Nat. Med. 7:693-698.
46. Aiuti, A., Webb, I.J., Bleul, C., Springer, T., and Gutierrez-Ramos, J.C. 1997. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J. Exp. Med. 185:111-120.
47. Kovacic, J.C., Muller, D.W., and Graham, R.M. 2007. Actions and therapeutic potential of G-CSF and GM-CSF in cardiovascular disease. J. Mol. Cell. Cardiol. 42:19-33.
48. Jin, D.K., et al. 2006. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat. Med. 12:557-567.
49. Shiba, Y., et al. 2007. M-CSF accelerates neointimal formation in the early phase after vascular injury in mice: the critical role of the SDF-1-CXCR4 system. Arterioscler. Thromb. Vasc. Biol. 27:283-289.
50. Moskovits, N., Kalinkovich, A., Bar, J., Lapidot, T., and Oren, M. 2006. p53 Attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Res. 66:10671-10676.
51. Mehta, S.A., et al. 2007. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion. Oncogene. 26:3329-3337.
52. Jung, J.E., et al. 2005. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J. 19:1296-1298.
53. Funamoto, M., et al. 2000. Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. J. Biol. Chem. 275:10561-10566.
54. Davis, C., Fischer, J., Ley, K., and Sarembock, I.J. 2003. The role of inflammation in vascular injury and repair. J. Thromb. Haemost. 1:1699-1709.
55. Walsh, K., Smith, R.C., and Kim, H.S. 2000. Vascular cell apoptosis in remodeling, restenosis, and plaque rupture. Circ. Res. 87:184-188.
56. Granada, J.F., et al. 2005. Single perivascular delivery of mitomycin C stimulates p21 expression and inhibits neointima formation in rat arteries. Arterioscler. Thromb. Vasc. Biol. 25:2343-2348.
57. Smith, R.C., et al. 1997. p21CIP1-mediated inhibition of cell proliferation by overexpression of the gax homeodomain gene. Genes Dev. 11:1674-1689.
58. De Clercq, E. 2003. The bicyclam AMD3100 story. Nat. Rev. Drug Discov. 2:581-587.
59. Nuhrenberg, T.G., et al. 2005. Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty. FASEB J. 19:246-248.
60. Togel, F., Isaac, J., Hu, Z., Weiss, K., and Westenfelder, C. 2005. Renal SDF-1 signals mobilization and homing of CXCR4-positive cells to the kidney after ischemic injury. Kidney Int. 67:1772-1784.
61. Butler, J.M., et al. 2005. SDF-1 is both necessary and sufficient to promote proliferative retinopathy. J. Clin. Invest. 115:86-93.
62. Abbott, J.D., et al. 2004. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation 110:3300-3305.
63. Zernecke, A., et al. 2005. SDF-1alpha/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ. Res. 96:784-791.
64. Karshovska, E., et al. 2007. Expression of HIF-1alpha in injured arteries controls SDF-1alpha mediated neointima formation in apolipoprotein E deficient mice. Arterioscler. Thromb. Vasc. Biol. 27:2540-2547.
65. Giraud, S., Hurlstone, A., Avril, S., and Coqueret, O. 2004. Implication of BRG1 and cdk9 in the STAT3-mediated activation of the p21waf1 gene. Oncogene. 23:7391-7398.
66. Niu, G., et al. 2005. Role of Stat3 in regulating p53 expression and function. Mol. Cell. Biol. 25:7432-7440.